Active, Not Recruiting
Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy - CA209-654
Updated: 25 April, 2022 | ClinicalTrials.gov
Gender(s)
Age Range
Active, Not Recruiting
Inclusion Criteria: For Cohort 1 and 2: (Recruitment ended by 02/20/2020) - Advanced melanoma (Stage III/Stage IV) - Histologically confirmed diagnosis - Treatment decision for nivolumab monotherapy or nivolumab/ipilimumab combination therapy has already been taken For Cohort 3: (Recruitment ended by 08/31/2020) - Primary diagnosis of advanced melanoma after complete surgical tumor resection and no evidence of disease - Treatment decision for adjuvant nivolumab therapy has already been taken Exclusion Criteria: For Cohort 1 and 2: (Recruitment ended by 02/20/2020) - Current primary diagnosis of a cancer other than advanced melanoma, that requires systemic or other treatment or has not been treated curatively (as per discretion of the investigator) - Previous treatment with nivolumab, for nivolumab monotherapy cohort only - Current active participation in an interventional clinical trial For Cohort 3: (Recruitment ended by 08/31/2020) - Current diagnosis of persisting advanced melanoma or a cancer other than advanced melanoma that requires systemic or other treatment or has not been treated curatively (as per discretion of the investigator) - Current active participation in an interventional clinical trial Other protocol-defined inclusion/exclusion criteria apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
